XML 29 R30.htm IDEA: XBRL DOCUMENT v2.4.0.6
Acquisitions (Details 1) (USD $)
3 Months Ended
Mar. 31, 2012
years
Mar. 31, 2011
Jan. 05, 2011
Mar. 31, 2012
R&D- and commercialization-based milestones [Member]
Mar. 31, 2012
revenue-based payments [Member]
Jan. 04, 2011
Sadra Medical Inc [Member]
Jan. 05, 2011
Intelect Medical Inc [Member]
Mar. 31, 2012
2011 Acquisitions [Member]
Mar. 31, 2012
Maximum [Member]
Technology-related [Member]
Mar. 31, 2012
Maximum [Member]
R&D- and commercialization-based milestones [Member]
Mar. 31, 2012
Maximum [Member]
revenue-based payments [Member]
Mar. 31, 2012
Minimum [Member]
Technology-related [Member]
Mar. 31, 2012
Minimum [Member]
R&D- and commercialization-based milestones [Member]
Mar. 31, 2012
Minimum [Member]
revenue-based payments [Member]
Mar. 31, 2012
Purchased research and development [Member]
Maximum [Member]
Mar. 31, 2012
Purchased research and development [Member]
Minimum [Member]
Business Acquisition [Line Items]                                
Pre-acquisition equity interest           14.00% 15.00%                  
Business Acquisition, Percentage of Voting Interests Acquired           86.00% 85.00%                  
Business Acquisition, Contingent Consideration, at Fair Value   $ 287,000,000   $ 180,000,000 $ 185,000,000     $ (287,000,000)                
Estimated fair value of prior equity ownership interest in Sadra and Intelect               55,000,000                
Business Acquisition, Cost of Acquired Entity, Purchase Price               712,000,000                
Gain On Transactions   38,000,000                            
Risk-adjusted discount rate for contingent consideration                   3.00% 20.00%   1.20% 12.00%    
contingent consideration liability, probability of payment                   85.00% 100.00%   50.00% 65.00%    
contingent consideration liability, projected year of payment                   2017 2018   2013 2012    
Allocation of purchase price to various intangible asset categories                                
Amortizable intangible assets 97,000,000                              
Indefinite-lived intangible assets 470,000,000                              
Business Acquisition, Purchse Price Allocation, Net Intangible Assets 567,000,000                              
Weighted Average Amortization Period (in years) 7.4                              
Risk Adjusted Discount Rate for Purchase Price Allocation                 25.00%     22.60%     30.00% 23.60%
Allocation of goodwill acquired to reportable segments                                
Goodwill 266,000,000                              
Estimated Total Cost To Complete In Process Research And Development Programs Acquired, low end of range 150,000,000                              
Estimated Total Cost To Complete In Process Research And Development Programs Acquired, high end of range 200,000,000                              
Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value     55,000,000                          
Business Acquisition, Cost of Acquired Entity, Transaction Costs $ 0 $ 0